Cleerly ISCHEMIA vs Tempus ECG-Low EF
AI Verdict
Choose Cleerly ISCHEMIA if…
Choose Cleerly ISCHEMIA if you require a comprehensive, non-invasive assessment of coronary artery disease, including detailed plaque characterization, stenosis severity, and vessel-level ischemia likelihood. This tool is ideal for guiding personalized diagnosis and treatment strategies based on advanced CCTA analysis.
View Cleerly ISCHEMIA →Choose Tempus ECG-Low EF if…
Choose Tempus ECG-Low EF if you need to quickly identify patients aged 40 or older who may be at risk of heart failure due to low left ventricular ejection fraction using a standard 12-lead ECG. This tool serves as an efficient screening aid to prompt further evaluation for LVEF abnormalities.
View Tempus ECG-Low EF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly ISCHEMIA | Tempus ECG-Low EF |
|---|---|---|
| Deployment | Web-based solution | Integrates with current ECG platforms and electronic health records (EHRs). |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Cleerly ISCHEMIACleerly ISCHEMIA offers a comprehensive interactive web-based platform with detailed reports and 3D models, allowing physicians to review results in depth and providing individualized medical insight. Its design is backed by formal usability evaluations. In contrast, Tempus ECG-Low EF, while providing a simple binary output, is explicitly not a standalone diagnostic tool and requires interpretation with other clinical data, potentially adding complexity to the overall diagnostic workflow.
Clinical Value
Cleerly ISCHEMIACleerly ISCHEMIA provides a more in-depth, diagnostic assessment, offering vessel-level ischemia likelihood, non-invasive FFR estimation, and detailed plaque characterization, which directly aids in personalized treatment planning and has shown prognostic value for MACE events. Tempus ECG-Low EF is a valuable screening tool for identifying patients at risk of low LVEF from a common test, but it is explicitly not a standalone diagnostic and requires further evaluation, making its direct clinical actionability lower.
Pricing & Value
Cleerly ISCHEMIAWhile both tools have opaque pricing requiring direct vendor contact, Cleerly ISCHEMIA benefits from being billable under a Category I CPTu00ae code (75580) for non-invasive FFR estimation, which signifies established medical necessity and can facilitate reimbursement for healthcare providers. No similar specific billing or reimbursement information was found for Tempus ECG-Low EF, giving Cleerly a clearer pathway for financial viability.
Enterprise Readiness
Cleerly ISCHEMIABoth tools are FDA-cleared, HIPAA compliant, and offer BAAs, which are foundational for enterprise adoption. Cleerly ISCHEMIA explicitly details a web-based platform, a dedicated data transfer solution (Cleerly Proxy provided without additional charge), and integration with PowerScribe via API, indicating robust and specific integration capabilities for radiology workflows. Tempus ECG-Low EF generally states 'integrated into healthcare facility workflows' and 'EHR integrations,' which are positive but less specific than Cleerly's stated integrations.
Innovation
Cleerly ISCHEMIACleerly ISCHEMIA demonstrates a higher degree of innovation by providing non-invasive fractional flow reserve (FFR) estimation and detailed coronary plaque characterization from CCTA, offering a comprehensive and less invasive alternative to traditional diagnostic methods and pushing the boundaries of non-invasive diagnostic depth. While Tempus ECG-Low EF innovates by applying AI to ECGs for LVEF detection, Cleerly's multi-dimensional analysis represents a more profound advancement in diagnostic capability.
Support & Docs
TieNeither the provided structured facts nor the web search results offer sufficient specific information regarding dedicated customer support channels, service level agreements, or comprehensive public documentation for either Cleerly ISCHEMIA or Tempus ECG-Low EF. Therefore, a definitive winner cannot be determined for this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly ISCHEMIA | Tempus ECG-Low EF |
|---|---|---|
| Name | Cleerly ISCHEMIA | Tempus ECG-Low EF |
| Company | Cleerly | Tempus AI |
| Description | FDA-cleared AI tool that analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. | FDA-cleared AI software that analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF u226440%) in patients 40 years or older at risk of heart failure. It provides a binary output to aid clinicians in further evaluation. |
| Primary Data Input | CCTA scans | 12-lead ECG recordings |
| Key Output | Vessel-level ischemia likelihood determination, coronary plaque characterization, stenosis severity assessment, 3D digital models, interactive web-based reports | Binary output (Low LVEF Detected / Not Detected) |
| Target Condition | Coronary artery ischemia | Low Left Ventricular Ejection Fraction (LVEF u226440%) |
| Specialties | Cardiology, Radiology | Cardiology, Emergency Medicine, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and Tempus ECG-Low EF.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly ISCHEMIA or Tempus ECG-Low EF
Backers
Who funded each tool's parent company.